Which patients benefit most from adjuvant aromatase inhibitors?: Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

G Viale; M M Regan; P Dell'Orto; M G Mastropasqua; E Maiorano; B B Rasmussen; G MacGrogan; J F Forbes; R J Paridaens; M Colleoni; I Láng; B Thürlimann; H Mouridsen; L Mauriac; R D Gelber; K N Price; A Goldhirsch; B A Gusterson; A S Coates; BIG 1-98 Collaborative and International Breast Cancer Study Groups

doi:10.1093/annonc/mdq738

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

G Viale, M M Regan, P Dell'Orto, M G Mastropasqua, E Maiorano, B B Rasmussen, G MacGrogan, J F Forbes, R J Paridaens, M Colleoni, I Láng, B Thürlimann, H Mouridsen, L Mauriac, R D Gelber, K N Price, A Goldhirsch, B A Gusterson, A S Coates, BIG 1-98 Collaborative and International Breast Cancer Study Groups

Patologiafdeling HGH

95 Citationer (Scopus)

Abstract

On average, aromatase inhibitors are better than tamoxifen when used as initial or sequential therapy for postmenopausal women with endocrine-responsive early breast cancer. Because there may be contraindications to their use based on side-effects or cost, we investigated subgroups in which aromatase inhibitors may be more or less important.

Originalsprog	Engelsk
Tidsskrift	Annals of Oncology
Vol/bind	22
Udgave nummer	10
Sider (fra-til)	2201-7
Antal sider	7
ISSN	0923-7534
DOI	https://doi.org/10.1093/annonc/mdq738
Status	Udgivet - 2011

Adgang til dokumentet

10.1093/annonc/mdq738

Andre filer og links

Link to publication in Scopus

Citationsformater

Viale, G., Regan, M. M., Dell'Orto, P., Mastropasqua, M. G., Maiorano, E., Rasmussen, B. B., MacGrogan, G., Forbes, J. F., Paridaens, R. J., Colleoni, M., Láng, I., Thürlimann, B., Mouridsen, H., Mauriac, L., Gelber, R. D., Price, K. N., Goldhirsch, A., Gusterson, B. A., Coates, A. S., & BIG 1-98 Collaborative and International Breast Cancer Study Groups (2011). Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Annals of Oncology, 22(10), 2201-7. https://doi.org/10.1093/annonc/mdq738

Viale, G, Regan, MM, Dell'Orto, P, Mastropasqua, MG, Maiorano, E, Rasmussen, BB, MacGrogan, G, Forbes, JF, Paridaens, RJ, Colleoni, M, Láng, I, Thürlimann, B, Mouridsen, H, Mauriac, L, Gelber, RD, Price, KN, Goldhirsch, A, Gusterson, BA, Coates, AS & BIG 1-98 Collaborative and International Breast Cancer Study Groups 2011, 'Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial', Annals of Oncology, bind 22, nr. 10, s. 2201-7. https://doi.org/10.1093/annonc/mdq738

@article{e9c98a7fbc974f3abd13236280b6f3d8,

title = "Which patients benefit most from adjuvant aromatase inhibitors?: Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial",

abstract = "On average, aromatase inhibitors are better than tamoxifen when used as initial or sequential therapy for postmenopausal women with endocrine-responsive early breast cancer. Because there may be contraindications to their use based on side-effects or cost, we investigated subgroups in which aromatase inhibitors may be more or less important.",

keywords = "Aged, Antineoplastic Combined Chemotherapy Protocols, Aromatase Inhibitors, Breast Neoplasms, Chemotherapy, Adjuvant, Double-Blind Method, Drug Administration Schedule, Female, Humans, Ki-67 Antigen, Middle Aged, Nitriles, Prognosis, Receptor, Epidermal Growth Factor, Receptors, Estrogen, Receptors, Progesterone, Tamoxifen, Triazoles",

author = "G Viale and Regan, \{M M\} and P Dell'Orto and Mastropasqua, \{M G\} and E Maiorano and Rasmussen, \{B B\} and G MacGrogan and Forbes, \{J F\} and Paridaens, \{R J\} and M Colleoni and I L{\'a}ng and B Th{\"u}rlimann and H Mouridsen and L Mauriac and Gelber, \{R D\} and Price, \{K N\} and A Goldhirsch and Gusterson, \{B A\} and Coates, \{A S\} and \{BIG 1-98 Collaborative and International Breast Cancer Study Groups\}",

year = "2011",

doi = "10.1093/annonc/mdq738",

language = "English",

volume = "22",

pages = "2201--7",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Limited",

number = "10",

}

TY - JOUR

T1 - Which patients benefit most from adjuvant aromatase inhibitors?

T2 - Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

AU - Viale, G

AU - Regan, M M

AU - Dell'Orto, P

AU - Mastropasqua, M G

AU - Maiorano, E

AU - Rasmussen, B B

AU - MacGrogan, G

AU - Forbes, J F

AU - Paridaens, R J

AU - Colleoni, M

AU - Láng, I

AU - Thürlimann, B

AU - Mouridsen, H

AU - Mauriac, L

AU - Gelber, R D

AU - Price, K N

AU - Goldhirsch, A

AU - Gusterson, B A

AU - Coates, A S

AU - BIG 1-98 Collaborative and International Breast Cancer Study Groups

PY - 2011

Y1 - 2011

N2 - On average, aromatase inhibitors are better than tamoxifen when used as initial or sequential therapy for postmenopausal women with endocrine-responsive early breast cancer. Because there may be contraindications to their use based on side-effects or cost, we investigated subgroups in which aromatase inhibitors may be more or less important.

AB - On average, aromatase inhibitors are better than tamoxifen when used as initial or sequential therapy for postmenopausal women with endocrine-responsive early breast cancer. Because there may be contraindications to their use based on side-effects or cost, we investigated subgroups in which aromatase inhibitors may be more or less important.

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Aromatase Inhibitors

KW - Breast Neoplasms

KW - Chemotherapy, Adjuvant

KW - Double-Blind Method

KW - Drug Administration Schedule

KW - Female

KW - Humans

KW - Ki-67 Antigen

KW - Middle Aged

KW - Nitriles

KW - Prognosis

KW - Receptor, Epidermal Growth Factor

KW - Receptors, Estrogen

KW - Receptors, Progesterone

KW - Tamoxifen

KW - Triazoles

UR - https://www.scopus.com/pages/publications/79959884829

U2 - 10.1093/annonc/mdq738

DO - 10.1093/annonc/mdq738

M3 - Journal article

C2 - 21335417

SN - 0923-7534

VL - 22

SP - 2201

EP - 2207

JO - Annals of Oncology

JF - Annals of Oncology

IS - 10

ER -

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater